Introduction:
Cerebral lymphoma is a rare and aggressive brain tumor. It accounts for 1% of all non-Hodgkin’s lymphomas (NHL), and 2% of all brain tumors. Untreated brain lymphoma has a very poor prognosis, with an overall life expectancy of around 1.5 months
Case presentation:
We report the case of a 35-year-old patient, with no previous pathological history, who presented for 3 weeks with deafness and recently aggravated otalgia. in MRI brain imaging revealed a formation initially suggestive of an aggressive meningioma, and in whom the histological study of the operative specimen was in favor of a diffuse large-cell non-germ-center B non-Hodgkin’s lymphoma.
Clinical Discussion:
Primary central nervous system lymphoma (PCNSL) is an extra-nodal non-Hodgkin’s lymphoma (NHL) localized to the brain, meninges, spinal cord and eyes. In 90% of cases, these are diffuse large B-cell lymphomas (DLBCL), the other types being poorly characterized low-grade lymphomas, T-cell lymphomas and Burkitt’s lymphomas. Magnetic resonance imaging (MRI) with gadolinium contrast is the gold standard for diagnosis which enhancement is homogeneous and well limited, frequently associated with perilesional vascular edema. In T2-weighted sequences, there is a weak signal with restricted diffusion on diffusion-weighted imaging (DWI). The management of brain lymphoma is currently based on chemotherapy with high-dose methotrexate (MTX) combined to the other agents, mainly rituximab.
Conclusion:
Cerebral lymphoma remains a non-negligible entity of central nervous system tumors, which can be confused with several other tumors, mainly glial and meningioma